Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.

Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G Ann Hematol. 2014 Feb,93(2):267-77. doi: 10.1007/s00277-013-1966-z. Epub 2013 Nov 30.

Bone-Targeted Therapy in Metastatic Breast Cancer – All Well-Established Knowledge?

Gampenrieder, SP, Rinnerthaler, G, Greil, R Breast Care (Basel). 2014 Oct,9(5):323-30. doi: 10.1159/000368710.

Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays – implications for response-guided therapy in genotype 1 infections.

Taylor N, Haschke-Becher E, Greil R, Strasser M, Oberkofler H. Antivir Ther. 2014,19(5):449-54. doi: 10.3851/IMP2723. Epub 2014 Jan 16.

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.

Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y J Antimicrob Chemother. 2014 Apr,69(4):1090-7. doi: 10.1093/jac/dkt474. Epub 2013 Nov 27.

Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

Huemer F, Gampenrieder SP, Schlattau A, Greil R. Clin Breast Cancer. 2014 Feb,14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28.

Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.

Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. World J Gastroenterol. 2014 May 28,20(20):6102-12. doi: 10.3748/wjg.v20.i20.6102.

Oxaliplatin, fluorouracil and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label randomised phase 3 trial.

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C Lancet Oncol. 2014 Jul,15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11.

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays, an ERIC-wide approach.

Te Raa GD, MalДЌikovГЎ J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-BГ©ral H, Greil R, Merkel O, PospГ­ЕЎilovГЎ S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP Br J Haematol. 2014 Nov,167(4):565-9. doi: 10.1111/bjh.13006. Epub 2014 Jun 30.

Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II IIIA and IIIB (TAX-AT 1.203 Trial).

Kocher F, Pircher A, Mohn-Staudner A, Romeder F, Duller W, Steinmaurer M, Eckmayr J, Schmid T, Hilbe W, Fiegl M, Greil R. Lung Cancer. 2014 Sep,85(3):395-400. doi: 10.1016/j.lungcan.2014.06.019. Epub 2014 Jul 3.

A randomized, open-label multicentre phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine cyclophosphamide and rituximab versus fludarabine cyclophosphamide and rituximab versus fludarabine cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC Br J Haematol. 2014 Nov,167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8.